A new study on early onset appendix cancer gives us one of the first real looks at how this disease behaves in people diagnosed before 50. A team at the University of Chicago, with co-authors including Dr. Kiran Turaga, published it in Annals of Surgical Oncology in June 2026, and it is open access, so you can read the whole thing yourself. I read research like this closely. My husband David was diagnosed with goblet cell adenocarcinoma, and that is what pulled me into this work. The study is small, a single hospital looking back at its own patient records, and the authors are upfront that their findings are early signals rather than settled answers. Even so, a few of those signals are worth knowing, because they touch on decisions you or someone you love may be facing right now.

What this study looked at

Who this study is about matters, because appendix cancer is not one disease. This study grouped several histologies together and analyzed them as one, under the umbrella of appendiceal adenocarcinoma. That included mucinous adenocarcinoma, colonic-type (nonmucinous) adenocarcinoma, signet ring cell adenocarcinoma, poorly differentiated adenocarcinoma, and goblet cell adenocarcinoma. Goblet cell was folded in because it tends to behave like high-grade disease and is often treated the same way. If your diagnosis is one of those, including signet ring, you were part of the population this study describes. The authors did not break out separate results for each subtype, though, so nothing here is specific to signet ring or any single type on its own. The study did not include low-grade or high-grade appendiceal mucinous neoplasms, the LAMN and HAMN tumors that can lead to pseudomyxoma peritonei, and it did not include neuroendocrine tumors. If your diagnosis is LAMN, HAMN, or PMP, this study is not describing your cancer.

Why early onset appendix cancer is getting attention

Appendix cancer is rare, but it is being diagnosed more often, and the increase is steepest in younger adults. Early onset appendix cancer is the fastest-rising early onset gastrointestinal cancer, climbing faster than the early onset colon and rectal cancers that have been getting headlines. In this study, more than a quarter of the patients were under 50. That is a lot for a cancer that most people, including many doctors, still think of as something that shows up later in life.

Part of how we close that gap is data. If you have been diagnosed, you can add your information to our patient data registry.

Follow-up may need to last longer

The most directly useful finding is about how long follow-up should continue. In this group, recurrences did not always happen in the first couple of years. Some showed up well after the five-year mark, the point where many people assume they are in the clear. Because of that, the Chicago team keeps watching their patients longer, often out to ten years, rather than closing the book at five. The study also pointed to younger patients who stayed cancer-free through the first two years still carrying a higher chance of the cancer returning later than older patients did, though the authors are careful to treat that as a signal rather than a settled finding. So if you were diagnosed young, it is worth asking your team whether your follow-up should run longer than the standard window.

Younger women and the ovaries

For women diagnosed young, the study raised a specific concern. A meaningful share of the younger women in this group already had the cancer involving their ovaries at the time of diagnosis, more often than you would expect from comparisons with colorectal cancer. This is the kind of thing that should be on the table early, not after the fact. It opens real questions about fertility, about whether and when to consider removing the ovaries, and about how to weigh those choices while you are also dealing with the cancer itself. If you are a younger woman with this diagnosis, fertility planning and the ovarian question are worth raising before treatment decisions get locked in.

More treatment did not mean more time

One finding sticks with me more than the others. The younger patients in this study were treated more aggressively than the older ones. They were more likely to receive bevacizumab and non-standard or experimental drugs, and they tended to go through more lines of therapy. Despite all of that extra treatment, they did not live longer overall than the older patients.

What the study could not tell us is just as important. It did not measure quality of life at all. So it cannot say whether that more aggressive treatment bought these patients better time, worse time, or simply more treatment. The authors flag this themselves, noting that intense treatment carries real costs in side effects and quality of life, and that those costs deserve careful thought before pushing harder in a young patient. That is not a reason to refuse treatment. It is a reason to ask a sharper question, the one in the box above.

What the tumors looked like

The study also sequenced tumors where that data was available. The most commonly altered gene was KRAS, followed by GNAS, TP53, and SMAD4. TP53 changes showed up more often in the younger group, though that difference did not reach statistical significance. Every tumor tested was microsatellite stable, which matters because microsatellite-stable tumors generally do not respond to the immunotherapy drugs that help in some other cancers. Goblet cell is personal for me, since it is David’s diagnosis, so I want to be clear about one thing here. Goblet cell adenocarcinoma tends to carry KRAS mutations far less often than the other appendiceal types, so the KRAS figure in this study describes the broader group and should not be read as applying to goblet cell specifically.

Questions to bring to your team

The thread running through all of this is that early onset appendix cancer may not behave like the same disease in a younger body, and that is worth saying out loud with your care team. These are the questions I would bring to my own next appointment.

None of this is settled. It is one small study from one hospital, looking backward at records, and the authors are careful to call their results signals for future research rather than conclusions. But signals are still worth paying attention to when they point at decisions you are facing now. The clearest message is that younger patients deserve care plans built for them, not borrowed from how the disease behaves in people decades older. Clinical trials are a big part of how that gets worked out, and being young and otherwise healthy can make you a strong candidate, so it is worth asking what trials you might fit. Dr. Kiran Turaga, Chief of Surgical Oncology at Yale and one of the co-authors on this study, leads a trial there for high-grade appendiceal cancer, and our recorded conversation with his team is linked below.

Related reading

Our series on signet ring cell appendix cancer
Watch our live event with Dr. Kiran Turaga’s team on their high-grade appendiceal trial

The study

Gujarathi R, et al. Survival Outcomes in Early Onset Appendiceal Adenocarcinoma (EOAA). Annals of Surgical Oncology, 2026.

Ask your questions about this study in the comments below, and I will answer what I can.